

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5539866

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ASCENDIS PHARMA GMBH	05/08/2019
RECEIVING PARTY DATA	
Name:	ASCENDIS PHARMA A/S
Street Address:	TUBORG BOULEVARD 5
City:	HELLERUP
State/Country:	DENMARK
Postal Code:	2900
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15502084
CORRESPONDENCE DATA	
Fax Number:	(212)588-0500
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	212-588-0800
Email:	docket@haugpartners.com, smccaskey@haugpartners.com
Correspondent Name:	HAUG PARTNERS LLP
Address Line 1:	745 FIFTH AVENUE
Address Line 2:	10TH FLOOR
Address Line 4:	NEW YORK, NEW YORK 10151
ATTORNEY DOCKET NUMBER:	514453-4004
NAME OF SUBMITTER:	JOSEPH W. TRELOAR
SIGNATURE:	/Joseph W. Treloar/
DATE SIGNED:	05/24/2019
Total Attachments: 2	
source=01903270#page1.tif	
source=01903270#page2.tif	

ASSIGNMENT

WHEREAS, Ascendis Pharma GmbH, having an address of Im Neuenheimer Feld 584, 69120 Heidelberg, Germany, (hereinafter referred to as Assignor) is the current owner by assignment of the invention described in United States Patent Application Serial No. 15/502,084 filed February 6, 2017, and of all United States Letters Patent to be obtained therefrom (hereinafter referred to as Invention);


AND WHEREAS, Ascendis Pharma A/S, having an address of Tuborg Boulevard 5, 2900, Hellerup, Denmark, (hereinafter referred to as Assignee) is desirous of acquiring the entire right, title, and interest in and to said Invention;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer, and set over unto said Assignee, and Assignee's legal representatives, successors, and assigns, the entire right, title, and interest in and to said Invention, including any continuations, continuations-in-part, divisions, reissues, re-examinations, or extensions thereof, including any and all patents of the United States and foreign countries that may be issued for said Invention;

UPON SAID CONSIDERATIONS, Assignor hereby agrees with Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents;

FURTHERMORE, Assignor covenants that Assignor will, at any time upon Assignee's request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and will render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said Invention, and in enforcing any rights or causes of action accruing as a result of such applications or patents, including giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing

covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of Assignor and Assignee.




[Assignor Representative Name]

[Assignor Representative Title]

Ascendis Pharma GmbH

Date: 08 May 2019




Signature of Witness

ROXANA LEMNARU

Printed Name of Witness

Date: 08-MAY-2019



MICHAEL WOLFF JENSEN
[Assignee Representative Name]

[Assignee Representative Title] CHAIRMAN

Ascendis Pharma A/S

Date: 09-MAY-2019

Kit Zacho

Signature of Witness

KIT ZACHO

Printed Name of Witness

Date: 9/5-2019